Correlate the following specific cellular and molecular biopsy findings with the targeted pharmacologic agent most appropriate for exploiting that underlying neoplastic mechanism.
- Biopsy of a breast mass in a premenopausal patient reveals invasive carcinoma with marked ERBB2 gene amplification.Trastuzumab
- Bone marrow aspirate from a patient presenting with marked leukocytosis shows myeloid cells harboring the t(9;22)(q34;q11) translocation.Imatinib
- Tissue analysis of metastatic non-small cell lung cancer in a lifelong non-smoker demonstrates an EML4-ALK inversion.Crizotinib
- Molecular profiling of recurrent high-grade serous ovarian carcinoma identifies a deleterious germline BRCA1 mutation.Olaparib
Answer
The correct matches pair the specific foundational molecular derangement identified in the biopsy with its corresponding targeted pharmacologic inhibitor.
Each correct pair accurately links a fundamental molecular derangement within a neoplastic cell to the pharmacologic agent specifically designed to inhibit or exploit that altered pathway.
Step-by-Step Solution
Key Concept
Targeted oncologic therapies exploit specific molecular vulnerabilities characteristic of distinct neoplastic processes, such as oncogene addiction (e.g., HER2, BCR-ABL, ALK) or synthetic lethality (e.g., PARP inhibition in BRCA-mutated cells).